FI3936130T3 - Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon - Google Patents

Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon Download PDF

Info

Publication number
FI3936130T3
FI3936130T3 FIEP21178882.3T FI21178882T FI3936130T3 FI 3936130 T3 FI3936130 T3 FI 3936130T3 FI 21178882 T FI21178882 T FI 21178882T FI 3936130 T3 FI3936130 T3 FI 3936130T3
Authority
FI
Finland
Prior art keywords
used according
medicinal composition
composition
hyperkinetic movement
inhibitor
Prior art date
Application number
FIEP21178882.3T
Other languages
English (en)
Finnish (fi)
Inventor
Christopher O'brien
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of FI3936130T3 publication Critical patent/FI3936130T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FIEP21178882.3T 2014-05-06 2015-05-06 Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon FI3936130T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
FI3936130T3 true FI3936130T3 (fi) 2024-04-23

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21178882.3T FI3936130T3 (fi) 2014-05-06 2015-05-06 Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon

Country Status (24)

Country Link
US (3) US20170071932A1 (https=)
EP (3) EP3139925B1 (https=)
JP (4) JP6635945B2 (https=)
KR (5) KR20200133003A (https=)
CN (3) CN106456629A (https=)
AU (1) AU2015256012B2 (https=)
CA (1) CA2947736C (https=)
CY (1) CY1125058T1 (https=)
DK (2) DK3936130T3 (https=)
ES (2) ES2976207T3 (https=)
FI (1) FI3936130T3 (https=)
HR (2) HRP20240459T1 (https=)
HU (2) HUE057839T2 (https=)
IL (1) IL248745B (https=)
LT (2) LT3936130T (https=)
MX (1) MX387625B (https=)
NZ (1) NZ725826A (https=)
PL (2) PL3936130T3 (https=)
PT (2) PT3139925T (https=)
RS (2) RS65359B1 (https=)
RU (1) RU2753740C2 (https=)
SI (2) SI3139925T1 (https=)
SM (2) SMT202400199T1 (https=)
WO (1) WO2015171802A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193767A (en) * 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
EP3568394A1 (en) 2017-01-10 2019-11-20 Sandoz AG Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
CN110678181A (zh) * 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CA3081709A1 (en) 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
EP3784237B1 (en) * 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MA55893A (fr) * 2019-05-09 2022-03-16 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2081929T3 (pl) * 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
NZ760790A (en) * 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
EP4389227A3 (en) 2024-09-04
JP2017514850A (ja) 2017-06-08
CN106456629A (zh) 2017-02-22
ES2976207T3 (es) 2024-07-26
EP3139925B1 (en) 2021-12-01
JP2024153782A (ja) 2024-10-29
EP3936130A1 (en) 2022-01-12
IL248745B (en) 2022-07-01
PT3139925T (pt) 2022-01-26
ES2904526T3 (es) 2022-04-05
CN112741835A (zh) 2021-05-04
MX387625B (es) 2025-03-18
RU2016147523A (ru) 2018-06-08
JP2019218407A (ja) 2019-12-26
SMT202400199T1 (it) 2024-07-09
IL248745A0 (en) 2017-01-31
CA2947736A1 (en) 2015-11-12
HUE057839T2 (hu) 2022-06-28
CY1125058T1 (el) 2023-06-09
NZ725826A (en) 2023-05-26
SMT202200193T1 (it) 2022-07-21
AU2015256012A1 (en) 2016-11-24
PT3936130T (pt) 2024-04-17
US20200101063A1 (en) 2020-04-02
DK3936130T3 (da) 2024-03-25
RU2753740C2 (ru) 2021-08-23
KR20200133003A (ko) 2020-11-25
HRP20220025T1 (hr) 2022-04-01
DK3139925T3 (da) 2021-12-20
SI3139925T1 (sl) 2022-04-29
RS65359B1 (sr) 2024-04-30
LT3139925T (lt) 2022-01-25
KR20160147044A (ko) 2016-12-21
RS62782B1 (sr) 2022-01-31
MX2016014429A (es) 2017-04-06
CA2947736C (en) 2023-04-18
JP2021191799A (ja) 2021-12-16
EP4389227A2 (en) 2024-06-26
US20210196702A1 (en) 2021-07-01
HRP20240459T1 (hr) 2024-06-21
JP6635945B2 (ja) 2020-01-29
HUE066361T2 (hu) 2024-07-28
EP3139925A1 (en) 2017-03-15
WO2015171802A1 (en) 2015-11-12
KR20240011255A (ko) 2024-01-25
PL3936130T3 (pl) 2024-06-10
KR20220140647A (ko) 2022-10-18
AU2015256012B2 (en) 2020-07-23
RU2016147523A3 (https=) 2018-12-28
PL3139925T3 (pl) 2022-03-21
KR20250029267A (ko) 2025-03-04
LT3936130T (lt) 2024-04-25
SI3936130T1 (sl) 2024-05-31
CN112741836A (zh) 2021-05-04
EP3936130B1 (en) 2024-02-14
US20170071932A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2015038135A5 (https=)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
EA201270041A1 (ru) Лечение рассеянного склероза лаквинимодом
JP2017506624A5 (https=)
JP2015519329A5 (https=)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2014198723A5 (https=)
Kukushkin et al. Results of a randomized double blind parallel study on the efficacy and safety of tolpersione in patients with acute nonspecific low back pain
ME02474B (me) Terapijski režimi
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2017507142A5 (https=)
ZA202000028B (en) Use of vibegron to treat overactive bladder
JP2016505050A5 (https=)
RU2020123405A (ru) Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
HRP20200473T1 (hr) Dimetilaminomikeliolid za uporabu u tretmanu pulmonarne fibroze